Results from Cardiovascular Outcome Trials in Diabetes.
UGC Endocrinología y Nutrición, Hospital Universitario San Cecilio, Complejo Hospitalario Universitario de Granada, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, España. Electronic address: mmt@mamuto.es.
Manuel
M
Muñoz Torres
UGC Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España.
Araceli
A
Muñoz Garach
D001559:Benzhydryl Compounds / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D048909:Diabetes Complications / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor / Q000037:antagonists & inhibitors; D005960:Glucosides / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D016896:Treatment Outcome
D001559:Benzhydryl Compounds; D054873:Dipeptidyl-Peptidase IV Inhibitors; D000067757:Glucagon-Like Peptide-1 Receptor; D005960:Glucosides; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C570240:empagliflozin